Clinical Trial Update: Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update evaluating nivolumab after combined modality therapy for high-risk stage II-IIIB anal cancer; the trial is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING